- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00155376
Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography
November 25, 2005 updated by: National Taiwan University Hospital
Morphine can induce constriction of sphincter of oddi and glucagon can facilitate bile secretion and dilatation of bile duct.
We conduct this randomized double blinded study to evaluate the effect of enhancement in MRCP using intravenous morphine and glucagon.
Study Overview
Detailed Description
Morphine can induce constriction of sphincter of oddi and glucagon can facilitate bile secretion and dilatation of bile duct.
We conduct this randomized double blinded study to evaluate the effect of enhancement in MRCP using intravenous morphine and glucagon.
Study Type
Interventional
Enrollment
100
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
province of Taiwan
-
Taipei, province of Taiwan, Taiwan, 100
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Yuan-Heng Mo, MD
- Email: jamesmyh@ha.mc.ntu.edu.tw
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- normal volunteer
- living liver donor
Exclusion Criteria:
- COPD
- chronic liver disease
- hypersensitive to glucagon
- DM
- insulinoma
- glucagonoma
- pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
MRCP visibility
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Hon-Man Liu, MD, National Taiwan University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2005
Study Completion
September 1, 2005
Study Registration Dates
First Submitted
September 8, 2005
First Submitted That Met QC Criteria
September 8, 2005
First Posted (Estimate)
September 12, 2005
Study Record Updates
Last Update Posted (Estimate)
November 28, 2005
Last Update Submitted That Met QC Criteria
November 25, 2005
Last Verified
April 1, 2005
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Liver Diseases
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Gastrointestinal Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Analgesics, Opioid
- Narcotics
- Glucagon
- Morphine
Other Study ID Numbers
- 940104
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Disease
-
HaEmek Medical Center, IsraelTerminatedPatients With Fatty Liver DiseaseIsrael
-
Assistance Publique - Hôpitaux de ParisCompletedNonalcoholic Fatty Liver Disease (NAFLD)France
-
Massachusetts General HospitalCompletedNonalcoholic Fatty Liver Disease (NAFLD)United States
-
Columbia UniversityGlaxoSmithKlineCompletedNon-Alcoholic Fatty Liver DiseaseUnited States
-
Kowa Company, Ltd.CompletedNon-Alcoholic Fatty Liver DiseaseJapan
-
Miriam Vos, MDImmuron Ltd.; Advanced MR Analytics ABCompletedNonalcoholic Fatty Liver Disease (NAFLD)United States
-
Beijing Chao Yang HospitalUnknownLiver Transplantation | End Stage Liver DIseaseChina
-
Saluz Investigación S. C.RecruitingMetabolic Associated Fatty Liver DiseaseMexico
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Not yet recruitingMetabolic Associated Fatty Liver Disease
-
Nanfang Hospital of Southern Medical UniversityRecruitingMetabolic Associated Fatty Liver DiseaseChina
Clinical Trials on morphine and glucagon
-
Zosano Pharma CorporationCompleted
-
Xeris PharmaceuticalsCompletedHypoglycemia | Diabetes Mellitus, Type 1United States, Canada
-
Zealand PharmaCompletedDiabetes Mellitus Type 1Germany
-
Eli Lilly and CompanyLocemia Solutions ULCCompleted
-
Eli Lilly and CompanyLocemia Solutions ULCCompletedDiabetes Mellitus | Drug-specific AntibodiesCanada
-
Hvidovre University HospitalTechnical University of DenmarkCompletedType 1 Diabetes MellitusDenmark
-
Insel Gruppe AG, University Hospital BernWithdrawn
-
The University of Texas Health Science Center at...South Texas Veterans Health Care SystemActive, not recruitingInsulin SensitivityUnited States
-
Xeris PharmaceuticalsEmpiristat, Inc.CompletedType 1 Diabetes Mellitus | Severe Hypoglycemia | Insulin HypoglycemiaUnited States, Canada, Austria
-
Steven J. Russell, MD, PhDCompletedType 1 DiabetesUnited States